Post-TB Lung Disease: LIBRE Pilot Intervention Insights

Understanding Post-TB Lung Disease (PTLD)

• 💡 Post-TB Lung Disease (PTLD) is a chronic respiratory abnormality, with or without symptoms, attributable to previous tuberculosis. It encompasses a wide range of conditions affecting airways, lung tissue, pleura, and even cardiac function.
• 📊 Up to 60% of people cured of TB may develop some form of PTLD, potentially affecting around 90 million individuals globally. This represents an enormous and often unaddressed public health challenge.
• ⚠️ PTLD significantly impacts Disability Adjusted Life Years (DALYs), with nearly 50% of TB-related DALYs occurring in the post-TB period, especially for young adults who face long-term impairment.

Challenges in PTLD Care

• 🔍 Current TB care primarily focuses on breaking the chain of transmission and ruling out active TB, often neglecting post-treatment sequelae. Routine PTLD screening is not standard practice globally.
• 🚧 The World Health Organization (WHO) guidance shows hesitancy in recommending PTLD interventions compared to active TB diagnostics, highlighting a gap in formal care pathways.
• 🧠 A paradigm shift is needed from a disease or infectiousness control-centered model to a person-centered model of care, acknowledging the long-term health needs of TB survivors.

Diagnostic Approaches & Tools

• 🔬 A variety of tools can be borrowed from other chronic respiratory diseases for PTLD diagnosis, including clinical examinations and blood tests.
• 📝 Questionnaires like the COPD Assessment Test (CAT), Modified Medical Research Council (MMRC) breathlessness scale, and St. George's Respiratory Questionnaire are used to assess symptoms and quality of life.
• 🩺 Lung function tests (e.g., spirometry, oscillometry), imaging (X-rays, CT scans), and functional assessments (e.g., 6-minute walk test) provide objective measures of lung damage and physical capacity.

The LIBRE Pilot Intervention in Peru

• 🇵🇪 The LIBRE pilot study in Lima, Peru, aimed to simulate post-TB evaluation and assess the feasibility, acceptability, cost, and effectiveness of an intervention for PTLD.
• ✅ Participants were screened using MMRC and CAT scores to identify those with significant respiratory symptoms after successful TB treatment.
• 🏋️ The intervention included pulmonary rehabilitation (video-based, 8 weeks, twice weekly) and, for more severe cases identified by spirometry, inhaled pharmacotherapy (short- or long-acting bronchodilators).

LIBRE Study Findings & Implications

• 📈 The study with 40 participants found that while few had spirometry impairment, many reported symptoms and showed significant abnormalities on X-rays, indicating lung damage.
• 🤝 The intervention showed moderate acceptability (70% session completion) and feasibility with dedicated resources, though challenges included technology, time constraints, and a desire for community.
• 💰 The estimated cost was $270-$415 per participant, considered manageable within Peru's healthcare system. Self-reported quality of life improved, but objective functional tests did not show significant change in this small pilot.
• 🚀 Peru is now repurposing COVID rehab centers for general pulmonary rehabilitation, and the national TB program is recommending routine PTLD screening, signaling a positive shift towards formalizing post-TB care.

Future Directions & Hopes

• 🌱 Future efforts should focus on preventing TB (vaccines, preventive therapy) and secondary prevention during treatment to minimize immune-mediated lung damage.
• 🗣️ There's a need to normalize lifelong care for TB survivors, ensuring ongoing screening and access to necessary services, moving beyond just infectiousness control.
• 🤝 Patient advocacy, creative partnerships, and leveraging new technologies like AI for diagnostics, alongside collaboration with other chronic respiratory disease groups, are crucial for advancing PTLD care.